What are the precautions for patients taking Sunvozertinib?

Suvozertinib (Sunvozertinib) is a new third-generation EGFRtyrosine kinase inhibitor (EGFR-TKI) developed locally in China. It is mainly used to treat patients with EGFR Exon 20 insertion mutations (EGFR 20ins) non-small cell lung cancer (NSCLC) patients. Its launch fills the clinical gap in the treatment of this type of mutation. However, like all targeted drugs, there are many precautions during the use of suvotinib. Patients need to use the medication regularly under the guidance of a doctor to better achieve efficacy, reduce the risk of side effects, and ensure medication safety.

1. Take the medicine strictly as directed by the doctor, and do not change the dosage without authorization

Suvotinib is a prescription drug and should be used under the guidance of a specialist. The currently recommended standard dose is 200mg administered orally once daily. There is no strict limit on the time of taking, but it is recommended to take it after meals to reduce gastrointestinal irritation. It is prohibited to increase or decrease the dose, discontinue medication, or change medicines on your own during medication. Especially when side effects occur, you should inform your doctor as soon as possible, and professionals will judge whether the dose needs to be adjusted (such as reducing to 200mg or 100mg) or suspending treatment. Once the patient misses a dose for some reason, if it is far away from the next dose time, he can take it in time; if it is close to the next dose time, it is recommended to skip that time and it is strictly forbidden to double the dose.

2. Be vigilant and monitor common side effects

Although suvotinib is generally well tolerated, some adverse reactions may still occur during the medication, and patients should be vigilant. The most common side effects include rash, diarrhea, nausea, stomatitis, abnormal liver function, decreased appetite, etc. In rare cases, more serious adverse reactions may occur, such as pneumonia-like symptoms (such as cough, difficulty breathing) or severe liver damage. Therefore, it is recommended that patients regularly monitor liver function (ALT/AST), kidney function, electrolyte levels and electrocardiogram during medication to detect potential risks in a timely manner. If persistent diarrhea, severe rash, or other unbearable discomfort occurs, seek medical attention immediately.

3. Pay attention to drug interactions and contraindications

Suvotinib is an oral targeted drug, its metabolism mainly depends on the liverCYP3Aenzyme system and therefore have potential interactions with drugs that are closely related to the enzyme activity. For example, grapefruit juice, anti-epileptic drugs (such as carbamazepine), rifampicin, ketoconazole, etc. may enhance or inhibit the metabolism of suvotinib, thereby affecting drug concentration, and should be avoided in combination with them. In addition, patients with severe hepatic and renal insufficiency should exercise extreme caution when using this product, and adjust the dose or switch to other regimens if necessary. Pregnant and lactating women should avoid using it because animal experiments have shown that it may be teratogenic to the fetus, and there is insufficient human research data.

4. Improve treatment quality by combining efficacy evaluation and life management

Treatment with suvotinib is a long-term process that requires a comprehensive management plan formulated by a physician, including regular imaging examinations (such as CT or PET- CT) and tumor marker detection (such as CEA, CYFRA21-1) to judge the efficacy. In addition, patients should maintain good living habits during medication, such as regular diet, adequate sleep, moderate exercise, and avoid smoking, drinking, and exposure to polluted environments to improve the body's immunity and drug metabolism. Because suvotinib may cause skin photosensitivity reactions, patients are advised to use sun protection when going out and avoid prolonged exposure to the sun.

Suvotinib, as an innovative targeted drug independently developed in China for EGFR Exon20ins mutated non-small cell lung cancer, provides an effective treatment option for patients with specific gene mutations. However, the realization of its curative effect cannot be achieved without the patient's attention and persistence in the details of medication. Only by strictly following medical instructions, paying close attention to adverse reactions, paying attention to drug interactions, and cooperating with monitoring and examinations can the therapeutic effect of suvotinib be maximized, extend the patient's survival period, and improve the quality of life. For any questions during the medication process, it is recommended to communicate with the attending doctor in a timely manner and never make any judgment on your own.

Reference materials:https://www.drugs.com/